Discordant Hormonal Status of Breast Cancer.
Discordant Hormonal Status Between Primary Tumor and Axillary Lymph Node in Breast Cancer Patients.
1 other identifier
observational
105
1 country
1
Brief Summary
The purpose of this study is to determine discordant hormonal status of primary breast tumor and metastatic breast cancer cells at regional lymph nodes in node positive breast cancer patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2011
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2012
CompletedFirst Submitted
Initial submission to the registry
September 10, 2013
CompletedFirst Posted
Study publicly available on registry
September 16, 2013
CompletedSeptember 20, 2013
September 1, 2013
Same day
September 10, 2013
September 19, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
Association of hormonal status between primary breast tumor and axillary lymph nodes
Association of estrogen and progesterone status between primary breast tumor and axillary lymph nodes was analyzed by using the χ2 test
Up to 1 year
Study Arms (2)
Primary Breast Tumor
Immunohistochemical staining of paraffin embedded tissue blocks of primary breast tumor for estrogen and progesterone receptors was performed.
Axillary Lymph Nodes.
Immunohistochemical staining of paraffin embedded tissue blocks of axillary lymph nodes for estrogen and progesterone receptors was performed.
Eligibility Criteria
Breast Cancer Patients Stage I,II and III.
You may qualify if:
- Breast cancer patients stage I,II and III with axillary lymph nodes metastasis.
You may not qualify if:
- Breast cancer patients stage I,II and III without axillary lymph nodes metastasis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Cancer Institute, Thailand.
Ratchathewi, Bangkok, 10400, Thailand
Related Publications (2)
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004 Aug 19;351(8):781-91. doi: 10.1056/NEJMoa040766.
PMID: 15317891BACKGROUNDCristofanilli M. The biological information obtainable from circulating tumor cells. Breast. 2009 Oct;18 Suppl 3:S38-40. doi: 10.1016/S0960-9776(09)70270-X.
PMID: 19914540BACKGROUND
Biospecimen
Paraffin embedded tissue blocks of primary breast tumor and axillary lymph nodes.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
AKANIST PIYAPANT, MD.,FRCST.
National Cancer Institute, Thailand
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD.,FRCST. Surgical Oncologist.
Study Record Dates
First Submitted
September 10, 2013
First Posted
September 16, 2013
Study Start
April 1, 2011
Primary Completion
April 1, 2011
Study Completion
April 1, 2012
Last Updated
September 20, 2013
Record last verified: 2013-09